Evidence map›Paper›PMID 30450208›Full record

ArticleJournal of materials chemistry. B2018

A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis.

Ting Liu, Changzheng Shi, Linqi Duan, Zehang Zhang, Liangping Luo, Shreya Goel, Weibo Cai, Tianfeng Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of materials chemistry. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. TME-Related Biomimetic Strategies Against Cancer.International journal of nanomedicine · 2024
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Mechanisms for Tuning Engineered Nanomaterials to Enhance Radiation Therapy of Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ting LiuThe First Affiliated Hospital, and Department of Chemistry, Jinan University, Guangzhou 510632, China.
Changzheng ShiThe First Affiliated Hospital, and Department of Chemistry, Jinan University, Guangzhou 510632, China.
Linqi DuanThe First Affiliated Hospital, and Department of Chemistry, Jinan University, Guangzhou 510632, China.
Zehang ZhangThe First Affiliated Hospital, and Department of Chemistry, Jinan University, Guangzhou 510632, China.
Liangping LuoThe First Affiliated Hospital, and Department of Chemistry, Jinan University, Guangzhou 510632, China.
Shreya GoelDepartments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.
Weibo CaiDepartments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.
Tianfeng ChenThe First Affiliated Hospital, and Department of Chemistry, Jinan University, Guangzhou 510632, China.
First Affiliated Hospital of Chinese PLA General Hospital · CNUniversity of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

Radiotherapy is a vitally important strategy for clinical treatment of malignant cancers. Therefore, rational design and development of radiosensitizers that could enhance radiotherapeutic efficacy has attracted tremendous attention. Antiangiogenesis therapy could be a potentially effective strategy to regulate tumor growth and metastasis due to angiogenesis plays a pivotal role for tumor growth, invasion and metastasis to other organs. Herein, we have rationally designed a smart and effective nanosystem by combining ultrasmall selenium nanoparticles and bevacizumab (Avastin

Identifiers

PMID30450208
PMCPMC6234506
OpenAlexW2810678239

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.